Tools
Tools
Neergheen, V, Chalasani, A, Wainwright, L, Yubero, D, Montero, R, Artuch, R and Hargreaves, IP (2017) Coenzyme Q10 in the treatment of mitochondrial disease. Journal of Inborn Errors of Metabolism and Screening. ISSN 2326-4098
|
Text
2326409817707771.pdf - Published Version Available under License Creative Commons Attribution. Download (314kB) | Preview |
Abstract
Currently, there is a paucity of available treatment strategies for oxidative phosphorylation disorders. Coenzyme Q10 (CoQ10) and related synthetic quinones are the only agents to date that have proven to be beneficial in the treatment of these heterogeneous disorders. The therapeutic efficacy of CoQ10 is not restricted to patients with an underlying CoQ10 deficiency and is thought to result from its ability to restore electron flow in the mitochondrial respiratory chain (MRC) as well as to increase the cellular antioxidant capacity. At present, however, there is no consensus on the appropriate dosage or therapeutic plasma level of CoQ10, and this information will be required before CoQ10 can be utilized effectively in the treatment of mitochondrial disease. The following review will outline our current knowledge on the use of CoQ10 in the treatment of MRC disorders and primary CoQ10 deficiencies. Keywords
| Item Type: | Article |
|---|---|
| Subjects: | Q Science > QH Natural history > QH301 Biology Q Science > QR Microbiology |
| Divisions: | Pharmacy & Biomolecular Sciences |
| Publisher: | Sage |
| Date Deposited: | 01 Jun 2018 09:13 |
| Last Modified: | 04 Sep 2021 10:26 |
| DOI or ID number: | 10.1177/2326409817707771 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/8754 |
 |
View Item |